With this result, and considering that KRAS/STK11-mutant lung cancer displays key differences in tumor associated immune cells as compared to other molecular subtypes and poorer response to immune checkpoint blockade (Skoulidis et al. 2015; Rosellini et al. 2022; Judd et al. 2021; Koyama et al. 2016), we assessed PD-L1 expression (encoded by the gene CD274) between the High PER1 and Low PER1 and the High PER1 and Low PER1 lung cancer patient cohorts. This evidence concerns the gene KRAS and lung carcinoma.